<DOC>
	<DOCNO>NCT00848354</DOCNO>
	<brief_summary>The purpose 2 phase , open-label study compare safety efficacy etanercept conventional Disease Modifying Antirheumatic Drug ( DMARD ) therapy Latin American subject moderate severe rheumatoid arthritis 128 week . Phase 1 randomize 24 week treatment period ; Phase 2 optional open-label 104 week period allow investigator choose continuation phase I treatment addition , discontinuation titration DMARD therapy already utilized study .</brief_summary>
	<brief_title>Open-Label Study Comparing Etanercept Conventional Disease Modifying Antirheumatic Drug ( DMARD ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis ( RA ) Currently receive suboptimal response stable dose methotrexate treatment Rheumatoid Arthritis ( RA ) Active Rheumatoid Arthritis ( RA ) time screen baseline Previous current treatment etanercept , tumor necrosis factoralpha inhibitor , biologic agent Concurrent treatment Disease Modifying Antirheumatic Drug ( DMARD ) , methotrexate , screen Receipt Disease Modifying Antirheumatic Drug ( DMARD ) , methotrexate , within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>enbrel</keyword>
	<keyword>moderate arthritis</keyword>
	<keyword>severe arthritis</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>